hepacivirus

Summary

Summary: A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.

Top Publications

  1. Jacobson I, Dore G, Foster G, Fried M, Radu M, Rafalsky V, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403-13 pubmed publisher
    ..The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection...
  2. Stenkvist J, Sonnerborg A, Weiland O. HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. J Viral Hepat. 2013;20:193-9 pubmed publisher
    ..This did not translate into a higher frequency of RVR or SVR. Hence, the clinical relevance of pretreatment analysis of IL28B polymorphisms in genotype 2 and 3 infected patients can be questioned in patients with expected high SVR rate. ..
  3. Li C, Njouom R, Pepin J, Nakano T, Bennett P, Pybus O, et al. Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1. J Gen Virol. 2013;94:1780-90 pubmed publisher
  4. Huys A, Thibault P, Wilson J. Modulation of hepatitis C virus RNA accumulation and translation by DDX6 and miR-122 are mediated by separate mechanisms. PLoS ONE. 2013;8:e67437 pubmed publisher
  5. Drexler J, Corman V, Müller M, Lukashev A, Gmyl A, Coutard B, et al. Evidence for novel hepaciviruses in rodents. PLoS Pathog. 2013;9:e1003438 pubmed publisher
    ..Three highly divergent rodent hepacivirus clades were detected in 27 (1.8%) of 1,465 European bank voles (Myodes glareolus) and 10 (1...
  6. Pawlotsky J. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol. 2013;369:321-42 pubmed publisher
    ..This chapter provides an overview of the current treatment of HCV infection and discusses the future of HCV therapy with new anti-HCV drugs. ..
  7. Lawitz E, Lalezari J, Hassanein T, Kowdley K, Poordad F, Sheikh A, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13:401-8 pubmed publisher
    ..Our findings lend support to the further assessment, in phase 2 and 3 trials, of sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks in treatment-naive patients with HCV genotype-1. Gilead Sciences. ..
  8. Wang C, Sun J, O Boyle D, Nower P, Valera L, Roberts S, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013;57:2054-65 pubmed publisher
    ..After the end of DCV treatment, viral fitness, rather than DCV resistance, probably determines which viral variants emerge as dominant in populations. ..
  9. Swadling L, Klenerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther. 2013;13:1109-24 pubmed publisher
    ..If these can be achieved, a vaccine against HCV appears a realistic goal. ..

More Information

Publications97

  1. Sautto G, Tarr A, Mancini N, Clementi M. Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol. 2013;2013:450963 pubmed publisher
  2. Pawlotsky J. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176-92 pubmed publisher
    ..Strategic choices, cost issues, HCV screening, and improving access to care in resource-constrained areas also are discussed. ..
  3. Lambert J, Bain V, Ryan E, Thomson A, Clandinin M. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology. 2013;57:1697-704 pubmed publisher
    ..Low PUFA levels combined with elevated lipogenesis suggests a role for dietary PUFA supplementation in HCV patients. ..
  4. Martin D, Uprichard S. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A. 2013;110:10777-82 pubmed publisher
    ..On the basis of these results, we conclude that TfR1 plays a role in HCV infection at the level of glycoprotein-mediated entry, acts after CD81, and possibly is involved in HCV particle internalization. ..
  5. Lin Y, Wu Y, Tseng C, Lin C, Chen W, Hsu Y, et al. Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation. PLoS ONE. 2013;8:e54466 pubmed publisher
    ..Collectively, (+)-epicatechin and (-)-epicatechin may serve as therapeutic supplements for treating HCV-related diseases. ..
  6. Zeuzem S, Berg T, Gane E, Ferenci P, Foster G, Fried M, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146:430-41.e6 pubmed publisher
  7. Fauvelle C, Lepiller Q, Felmlee D, Fofana I, Habersetzer F, Stoll Keller F, et al. Hepatitis C virus vaccines--progress and perspectives. Microb Pathog. 2013;58:66-72 pubmed publisher
  8. Niepmann M. Hepatitis C virus RNA translation. Curr Top Microbiol Immunol. 2013;369:143-66 pubmed publisher
  9. Heller T, Werner J, Rahman F, Mizukoshi E, Sobao Y, Gordon A, et al. Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J Infect Dis. 2013;208:1020-5 pubmed publisher
  10. Deng L, Zhong L, Struble E, Duan H, Ma L, Harman C, et al. Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. Proc Natl Acad Sci U S A. 2013;110:7418-22 pubmed publisher
    ..Our structural insights into the key determinants for the antibody-mediated neutralization may contribute to the immune prophylaxis of HCV infection and the development of an effective HCV vaccine. ..
  11. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13-8 pubmed publisher
    ..The effectiveness of these NS5A RCIs to exert efficacy in the clinic may depend on which inhibitor is used in combination with other antivirals. ..
  12. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083-91 pubmed publisher
    ..Hepatology 2014;59:2083-2091). ..
  13. Negash A, RAMOS H, Crochet N, Lau D, DOEHLE B, Papic N, et al. IL-1? production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 2013;9:e1003330 pubmed publisher
    ..Thus, strategies to suppress NLRP3 or IL-1? activity could offer therapeutic actions to reduce hepatic inflammation and mitigate disease. ..
  14. Lawitz E, Mangia A, WYLES D, Rodriguez Torres M, Hassanein T, Gordon S, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87 pubmed publisher
    ..In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection...
  15. Lindenbach B. Virion assembly and release. Curr Top Microbiol Immunol. 2013;369:199-218 pubmed publisher
    ..This chapter reviews our current understanding of these interactions and factors...
  16. Pantua H, Diao J, Ultsch M, Hazen M, Mathieu M, McCutcheon K, et al. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol. 2013;425:1899-1914 pubmed publisher
  17. Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-603 pubmed publisher
    ..In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis...
  18. Jacobson I, Gordon S, Kowdley K, Yoshida E, Rodriguez Torres M, Sulkowski M, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-77 pubmed publisher
    ..Funded by Gilead Sciences; POSITRON and FUSION ClinicalTrials.gov numbers, NCT01542788 and NCT01604850, respectively.). ..
  19. Barreca M, Manfroni G, Leyssen P, Winquist J, Kaushik Basu N, Paeshuyse J, et al. Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. J Med Chem. 2013;56:2270-82 pubmed publisher
    ..6 ?M, EC90 = 25.6 ?M, and CC50 > 180 ?M in the Huh 9-13 replicon system, thus providing a good starting point for further hit evolution. ..
  20. Kowdley K, Lawitz E, Crespo I, Hassanein T, Davis M, Demicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381:2100-7 pubmed publisher
    ..These results lend support to the further assessment of a 12 week sofosbuvir regimen in a broader population of patients with chronic HCV genotype-1 infection, including those with cirrhosis. Gilead Sciences. ..
  21. Dietz J, Schelhorn S, Fitting D, Mihm U, Susser S, Welker M, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol. 2013;87:6172-81 pubmed publisher
    ..152). We conclude that ribavirin exerts a mutagenic effect on the virus in patients with chronic hepatitis C by facilitating G-to-A and C-to-U nucleotide transitions. ..
  22. Bai Y, Zhou K, Doudna J. Hepatitis C virus 3'UTR regulates viral translation through direct interactions with the host translation machinery. Nucleic Acids Res. 2013;41:7861-74 pubmed publisher
    ..These observations support a model in which the HCV 3'UTR retains ribosome complexes during translation termination to facilitate efficient initiation of subsequent rounds of translation. ..
  23. Ploen D, Hafirassou M, Himmelsbach K, Sauter D, Biniossek M, Weiss T, et al. TIP47 plays a crucial role in the life cycle of hepatitis C virus. J Hepatol. 2013;58:1081-8 pubmed publisher
    ..Complete knockdown of TIP47 expression abolishes virus replication. TIP47 plays an essential role in the HCV life cycle. ..
  24. Pawlotsky J. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. 2013;59:375-82 pubmed publisher
    ..Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens. ..
  25. Mortimer S, Doudna J. Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure. Nucleic Acids Res. 2013;41:4230-40 pubmed publisher
    ..Thus, the miR-122:HCV ternary complex likely functions at other steps critical to the viral life cycle. ..
  26. Koutsoudakis G, Dragun J, P rez Del Pulgar S, Coto Llerena M, Mensa L, Crespo G, et al. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. PLoS ONE. 2012;7:e52651 pubmed publisher
  27. Salam K, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, et al. Psammaplin A inhibits hepatitis C virus NS3 helicase. J Nat Med. 2013;67:765-72 pubmed publisher
    ..1 and 6.3 ?M in subgenomic replicon cells derived from genotypes 1b and 2a, respectively. We postulate that psammaplin A is a potential anti-viral agent through the inhibition of ATPase, RNA binding and helicase activities of NS3...
  28. Zeuzem S, Soriano V, Asselah T, Bronowicki J, Lohse A, Mullhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369:630-9 pubmed publisher
    ..Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV) infection...
  29. Smith D, Bukh J, Kuiken C, Muerhoff A, Rice C, Stapleton J, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318-27 pubmed publisher
  30. Oakland T, Haselton K, Randall G. EWSR1 binds the hepatitis C virus cis-acting replication element and is required for efficient viral replication. J Virol. 2013;87:6625-34 pubmed publisher
    ..Finally, EWSR1 preferentially interacts with the CRE in the absence of the kissing interaction. This study implicates EWSR1 as a novel modulator of CRE function in HCV replication...
  31. Schvoerer E, Moenne Loccoz R, Murray J, Velay A, Turek M, Fofana I, et al. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. J Infect Dis. 2013;207:1306-15 pubmed publisher
  32. Catanese M, Loureiro J, Jones C, Dorner M, von Hahn T, Rice C. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol. 2013;87:8282-93 pubmed publisher
    ..Combination therapies targeting both the HCV glycoproteins and SR-BI may therefore hold promise for effective control of HCV dissemination. ..
  33. Ivanov A, Bartosch B, Smirnova O, Isaguliants M, Kochetkov S. HCV and oxidative stress in the liver. Viruses. 2013;5:439-69 pubmed publisher
    ..Furthermore, during last several years it has been shown that HCV modifies antioxidant defense mechanisms. The aim of this review is to summarize the present state of art in the field and to try to predict directions for future studies...
  34. Hajarizadeh B, Grebely J, Dore G. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-62 pubmed publisher
    ..Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alcohol intake and HIV co-infection. ..
  35. Lawitz E, Poordad F, Kowdley K, Cohen D, Podsadecki T, Siggelkow S, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol. 2013;59:18-23 pubmed publisher
  36. Conrad K, Giering F, Erfurth C, Neumann A, Fehr C, Meister G, et al. MicroRNA-122 dependent binding of Ago2 protein to hepatitis C virus RNA is associated with enhanced RNA stability and translation stimulation. PLoS ONE. 2013;8:e56272 pubmed publisher
    ..These results suggest that Ago2 protein is directly involved in loading miR-122 to the HCV RNA and mediating RNA stability and translation stimulation...
  37. Gu L, Tong W, Yuan M, Lu T, Li C, Lu L. An increased diversity of HCV isolates were characterized among 393 patients with liver disease in China representing six genotypes, 12 subtypes, and two novel genotype 6 variants. J Clin Virol. 2013;57:311-7 pubmed publisher
    ..A changed pattern could have also occurred among patients with liver disease...
  38. Pereira L, Martelli C, Moreira R, Merchan Hamman E, Stein A, Cardoso M, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis. 2013;13:60 pubmed publisher
    ..This article reports the first nationwide population-based survey conducted to estimate the seroprevalence of HCV antibodies and associated risk factors in the urban population of Brazil...
  39. Scheel T, Rice C. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19:837-49 pubmed publisher
  40. Zeisel M, Felmlee D, Baumert T. Hepatitis C virus entry. Curr Top Microbiol Immunol. 2013;369:87-112 pubmed publisher
  41. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013;3:514-20 pubmed publisher
    ..Mechanism of inhibition studies to elucidate the exquisite potency of these inhibitors have generated several working models. ..
  42. Grebely J, Page K, Sacks Davis R, Van der Loeff M, Rice T, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109-20 pubmed publisher
    ..26; 95% CI: 1.52, 3.34), and HCV genotype 1 (versus non-genotype 1; AHR: 1.56; 95% CI: 1.06, 2.30). The effect of IL28B genotype and HCV genotype on spontaneous clearance was greater among females, compared to males...
  43. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-92 pubmed publisher
    ..We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis...
  44. Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol. 2013;369:167-98 pubmed publisher
    ..This chapter summarizes our current knowledge on the role of viral and host cell proteins as well as cis-acting replication elements involved in the biogenesis of the membranous web and in viral RNA synthesis...
  45. Gonzalez Candelas F, Bracho M, Wrobel B, Moya A. Molecular evolution in court: analysis of a large hepatitis C virus outbreak from an evolving source. BMC Biol. 2013;11:76 pubmed publisher
    ..Here, we present the results of such an analysis that contributed to the conviction of an anesthetist as being responsible for the infection of 275 of his patients with hepatitis C virus...
  46. Zeuzem S, Dusheiko G, Salupere R, Mangia A, Flisiak R, Hyland R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993-2001 pubmed publisher
  47. Horwitz J, Dorner M, Friling T, Donovan B, Vogt A, Loureiro J, et al. Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein. Virology. 2013;439:23-33 pubmed publisher
    ..Expression of heterologous proteins within the HCV genome offers new opportunities to analyze HCV infection in experimental systems without perturbing functions of individual viral proteins...
  48. Janssen H, Reesink H, Lawitz E, Zeuzem S, Rodriguez Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685-94 pubmed publisher
    ..Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function...
  49. Li Y, Masaki T, Lemon S. miR-122 and the Hepatitis C RNA genome: more than just stability. RNA Biol. 2013;10:919-23 pubmed publisher
    ..Here, we consider the role of miR-122 in the viral lifecycle, and explore the possibility that it might function directly in viral RNA synthesis. ..
  50. Nichols D, Leão R, Basu A, Chudayeu M, de Moraes P, Talele T, et al. Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors. Chem Biol Drug Des. 2013;81:607-14 pubmed publisher
    ..NS5B-TP-1-8a interaction map provided insight into 8a binding and offered clues for future SAR optimization...
  51. López Prieto J, Gonzalez Reimers E, Alemán Valls M, de la Vega Prieto M, Abreu Gonzalez P, Pelazas González R, et al. Iron and proinflammatory cytokines in chronic hepatitis C virus infection. Biol Trace Elem Res. 2013;155:5-10 pubmed publisher
    ..Serum ferritin is higher among those with intense steatosis and also shows a (non-significant) trend to be associated with the more severe forms of hepatitis...
  52. Shanmugam S, Yi M. Efficiency of E2-p7 processing modulates production of infectious hepatitis C virus. J Virol. 2013;87:11255-66 pubmed publisher
    ..In conclusion, these results imply that effective release of E2 and p7 from the precursor E2-p7 promotes HCV production by enhancing NS2-associated virus assembly complex formation near LD...
  53. Ross Thriepland D, Amako Y, Harris M. The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release. J Gen Virol. 2013;94:1009-18 pubmed publisher
    ..Comparison of our data with a previously published analysis of the same region in genotype 1b revealed some important differences between the two genotypes of HCV...
  54. Guedj J, Dahari H, Rong L, Sansone N, Nettles R, Cotler S, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013;110:3991-6 pubmed publisher
    ..The multiscale modeling approach, validated with in vitro kinetic experiments, brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV...
  55. Gentzsch J, Brohm C, Steinmann E, Friesland M, Menzel N, Vieyres G, et al. hepatitis c Virus p7 is critical for capsid assembly and envelopment. PLoS Pathog. 2013;9:e1003355 pubmed publisher
    ..In summary, we provide novel insights into the sequence of HCV assembly events and essential functions of p7...
  56. Palau W, Masante C, Ventura M, Di Primo C. Direct evidence for RNA-RNA interactions at the 3' end of the Hepatitis C virus genome using surface plasmon resonance. RNA. 2013;19:982-91 pubmed publisher
    ..This result suggests also that the conformational dynamics of SL2 could play a crucial role for controlling the destiny of the genomic RNA...
  57. Billerbeck E, de Jong Y, Dorner M, de La Fuente C, Ploss A. Animal models for hepatitis C. Curr Top Microbiol Immunol. 2013;369:49-86 pubmed publisher
    ..Exciting new models and improvements in established models hold promise to further elucidate our understanding of chronic HCV infection...
  58. Bradrick S, Nagyal S, Novatt H. A miRNA-responsive cell-free translation system facilitates isolation of hepatitis C virus miRNP complexes. RNA. 2013;19:1159-69 pubmed publisher
    ..This combined approach may be generalizable to affinity purification of miRNP complexes for selected target mRNAs, allowing identification of miRNP components and RBPs that may contribute to regulation. ..
  59. Zona L, Lupberger J, Sidahmed Adrar N, Thumann C, Harris H, Barnes A, et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe. 2013;13:302-13 pubmed publisher
    ..HRas was also found to be relevant for entry of other viruses, including influenza. Our data demonstrate that viruses exploit HRas signaling for cellular entry by compartmentalization of entry factors and receptor trafficking...
  60. Meredith L, Harris H, Wilson G, Fletcher N, Balfe P, McKeating J. Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J Hepatol. 2013;58:1074-80 pubmed publisher
    ..However, limited information is available on the relative efficiency of these routes, our aim is to develop physiologically relevant assays to quantify these processes...
  61. Brownell J, Polyak S. Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res. 2013;19:1347-52 pubmed publisher
    ..We will also discuss potential host-directed therapies to slow or reverse HCV-induced inflammation that leads to fibrosis, cirrhosis, and HCCs...
  62. Gentile I, Borgia F, Buonomo A, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem. 2013;20:3733-42 pubmed
    ..Safety and tolerability of sofosbuvir appear to be excellent. In conclusion, sofosbuvir especially in interferon-free combinations represents a very promising option in the treatment of chronic hepatitis C. ..
  63. Kowdley K, Lawitz E, Poordad F, Cohen D, Nelson D, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222-32 pubmed publisher
  64. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, et al. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J Med Virol. 2013;85:1028-36 pubmed publisher
    ..It is concluded that it is difficult to predict at baseline the emergence of telaprevir-resistant variants after commencement of triple therapy in prior non-responders of HCV genotype 1, even with the use of ultra-deep sequencing...
  65. Ouyang B, Xie S, Berardi M, Zhao X, Dev J, Yu W, et al. Unusual architecture of the p7 channel from hepatitis C virus. Nature. 2013;498:521-5 pubmed publisher
    ..Our data provide a molecular explanation for p7-mediated cation conductance and its inhibition by adamantane derivatives...
  66. Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-82 pubmed publisher
  67. Jammart B, Michelet M, Pécheur E, Parent R, Bartosch B, Zoulim F, et al. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J Virol. 2013;87:5065-80 pubmed publisher
    ..This suggests that there is no correlation between the ability of cells to simultaneously replicate HCV as well as secrete VLDL and their capacity to produce LVPs...
  68. Sulkowski M, Gardiner D, Rodriguez Torres M, Reddy K, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-21 pubmed publisher
    ..We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3...
  69. Perales C, Beach N, Gallego I, Soria M, Quer J, Esteban J, et al. Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol. 2013;87:7593-607 pubmed publisher
    ..The results suggest that multiple, independent mutational pathways can confer IFN-? resistance to HCV and might explain why no unified picture has been obtained regarding IFN-? resistance in vivo...
  70. Fried M, Buti M, Dore G, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918-29 pubmed publisher
    ..The adverse event profile was generally similar across the SMV and placebo control groups, with the exception of mild reversible hyperbilirubinemia, without serum aminotransferase abnormalities, associated with higher doses of SMV...
  71. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482-96 pubmed publisher
  72. Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99:12-7 pubmed publisher
    ..Moreover, the natural polymorphisms in genotype 2b (i.e. S122R) and 3a (i.e. D168Q), with inherent PI drug resistance of up to 20 and 700 fold respectively, would explain why current PIs are primarily directed against genotype 1...
  73. Wilson J, Huys A. miR-122 promotion of the hepatitis C virus life cycle: sound in the silence. Wiley Interdiscip Rev RNA. 2013;4:665-76 pubmed publisher
    ..Used alone or in combination with other antiviral drugs, miR-122 antagonists could be useful to both inhibit the virus and provide selective pressure to inhibit the development of resistance...
  74. Sourisseau M, Michta M, Zony C, Israelow B, Hopcraft S, Narbus C, et al. Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog. 2013;9:e1003244 pubmed publisher
    ..These results fit a model where the tight junction region is the last to be encountered by the virion prior to internalization...
  75. Wahid A, Dubuisson J. Virus-neutralizing antibodies to hepatitis C virus. J Viral Hepat. 2013;20:369-76 pubmed publisher
    ..Finally, the recent identification of several highly conserved neutralizing epitopes provides some opportunities for the design and development of vaccine candidates that elicit a protective humoral immune response...
  76. Afridi S, Zahid M, Shabbir M, Hussain Z, Mukhtar N, Tipu M, et al. Prevalence of HCV genotypes in district Mardan. Virol J. 2013;10:90 pubmed publisher
    ..One example is district Mardan from where such data is available only from 17 individuals. Accordingly, the present study aimed at determining HCV genotypes distribution among 177 HCV RNA positive individuals from district Mardan...
  77. Arzumanyan A, Reis H, Feitelson M. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-35 pubmed publisher
    ..This Review outlines pathogenic mechanisms that seem to be common to both viruses and which suggest innovative approaches to the prevention and treatment of HCC...
  78. Hsu C, Kao J, Chao Y, Lin H, Fan Y, Huang C, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415-23 pubmed publisher
    ..Hepatitis C virus (HCV) infection has been linked to an increased risk of insulin resistance and carotid atherosclerosis...
  79. Li D, Long Y, Wang T, Xiao D, Zhang J, Guo Z, et al. Epidemiology of hepatitis C virus infection in highly endemic HBV areas in China. PLoS ONE. 2013;8:e54815 pubmed publisher
    ..From 2007 to 2011, the average reported incidence rate of hepatitis B was 634.56/100,000 people. However, studies assessing the epidemic features and risk factors of HCV in the general population of Wuwei City are limited...
  80. Afdhal N, Reddy K, Nelson D, Lawitz E, Gordon S, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-93 pubmed publisher
    ..Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need...
  81. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98 pubmed publisher
  82. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med. 2013;210:1109-16 pubmed publisher
    ..This novel step in understanding the genetic regulation of IL28B may have important implications for clinical practice, as the use of TT/G genotyping instead of rs12979860 would improve patient management...
  83. Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369:113-42 pubmed publisher
    ..This review summarizes current knowledge of the structure and function of the HCV proteins and highlights recent advances in the field...
  84. Quan P, Firth C, Conte J, Williams S, Zambrana Torrelio C, Anthony S, et al. Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc Natl Acad Sci U S A. 2013;110:8194-9 pubmed publisher
  85. Manfroni G, Cannalire R, Barreca M, Kaushik Basu N, Leyssen P, Winquist J, et al. The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors. J Med Chem. 2014;57:1952-63 pubmed publisher
    ..These results indicate that the 6-aminoquinolone scaffold is worthy of further investigation in the context of NS5B-targeted HCV drug discovery programs. ..
  86. Fontana R, Hughes E, Bifano M, Appelman H, Dimitrova D, Hindes R, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601-5 pubmed publisher
    ..The rapid and sustained suppression of HCV replication in this liver transplant recipient provides great promise for the use of combination oral antiviral regimens in other immunosuppressed and interferon refractory HCV patients...
  87. Alves R, Queiroz A, Pessoa M, da Silva E, Mazo D, Carrilho F, et al. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank. J Viral Hepat. 2013;20:414-21 pubmed publisher
    ..Likewise, genotype 1b isolates and genotype 1a sequences exhibited pre-existing mutations associated with resistance to Palm II and Thumb I polymerase inhibitors, respectively...
  88. Larrey D, Lohse A, Trepo C, Bronowicki J, Arasteh K, Bourliere M, et al. Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob Agents Chemother. 2013;57:4727-35 pubmed publisher
    ..P495 variants did not persist in follow-up without selective drug pressure. Deleobuvir monotherapy was generally well tolerated and demonstrated dose-dependent antiviral activity against HCV genotype 1 over 5 days. ..